Longevity & Aging · Metabolic & Cardiometabolic

insulin resistance and metabolic dysfunction increases Alzheimers disease risk

In plain terms: Does insulin resistance raise your risk of Alzheimer's?

Leans support(Association does not establish cause) Longevity & Aging 🔬 Includes disconfirming

Part of: • Insulin & Metabolic Aging

RefutedContestedStrong support

consensus score 0.64

Why the rating is limited: association does not establish cause.

The evidence can show that two things occur together, but cannot on its own establish that one causes the other.

Before this limit: strong support. Final rating: leans support.

Yes — insulin resistance and diabetes are robustly linked to higher dementia/Alzheimer's risk observationally and mechanistically, but interventional trials targeting brain insulin have so far failed, so causation and the type-3-diabetes label remain unproven.

📅 Last reviewed: 2026-07-14 ⓘ

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: Population patterns (Observational)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

10 support 0 contradict 2 tested null 2 mixed · 14 sources, 10 independent groups

What the evidence shows

Causal-review pass (2026-08-14) — `causal_basis: association-only`. The association is large, consistent and mechanistically attractive -- 13 observational appraisals, several high quality, across ARIC, Hisayama, Korean NHIS. And the causal tests have failed. The intranasal-insulin meta-analysis (s41436338) is `tested-null`, and the 2026 evoke RCT (s41865758, high quality) is `tested-null`.

The evidence (16)

Source	Grade	Stance	Quality	Finding
Ge T, Ding Y, Yan M, Zhao M, Hailili G, Wu M, Shen J, Liu X, Ma Y, Zhou D, Yuan C 2026 · J Gerontol A Biol Sci Med Sci	observational	supports	moderate	Prospective cohort found longitudinal increases in TyG index associated with higher incident dementia risk.
Sarnowski C, Huan T, Ma Y, Joehanes R, Beiser A, DeCarli CS, Heard-Costa NL, Levy D, Lin H, Liu CT, Liu C, Meigs JB, Satizabal CL, Florez JC, Hivert MF, Dupuis J, De Jager PL, Bennett DA, Seshadri S, Morrison AC 2023 · Clin Epigenetics	mechanism	supports	moderate	Multi-tissue epigenetic analysis identified shared methylation signatures linking insulin resistance and Alzheimer's disease at the CPT1A locus.
Morris JK, Vidoni ED, Mahnken JD, Montgomery RN, Johnson DK, Thyfault JP, Burns JM 2016 · Neurobiol Aging	observational	mixed	low	Cognitively impaired elderly showed greater insulin resistance than controls, but insulin infusion did not improve memory, complicating a direct causal claim.
Wei Y, Yang B, Wang J, Zhao W, Dai W, Xie R, Zhang L 2026 · Medicine (Baltimore)	observational	mixed	low	Cross-sectional NHANES analysis: higher cardiovascular health (Life's Essential 8) associated with better cognition; blood glucose was the second-largest contributing component (weight 0.19) after physical activity.
Gutierrez-Tordera L, Panisello L, García-Gonzalez P, Ruiz A, Cantero JL, Rojas-Criollo M, Mursil M, Atienza M, Novau-Ferré N, Mateu-Fabregat J, Mostafa H, Puig D, Folch J, Rashwan H, Marquié M, Boada M, Papandreou C, Bulló M 2025 · J Gerontol A Biol Sci Med Sci	observational	supports	moderate	Metabolic signature of insulin resistance was associated with progression from MCI to Alzheimer's dementia.
Rawlings AM, Sharrett AR, Schneider AL, Coresh J, Albert M, Couper D, Griswold M, Gottesman RF, Wagenknecht LE, Windham BG, Selvin E 2014 · Ann Intern Med	observational	supports	high	ARIC cohort: midlife diabetes (and prediabetes) associated with substantially greater 20-year cognitive decline, supporting a metabolic-dysfunction to cognition link.
Hong S, Han K, Park CY 2021 · Alzheimers Res Ther	observational	supports	high	Large population-based study found higher TyG index associated with elevated incident dementia risk.
Jun JE, Kim S, Jeong IK, Kim JH 2026 · Diabetes Obes Metab	observational	supports	high	Korean nationwide cohort (n=1,322,651): dementia incidence and adjusted HRs vs non-diabetic were 1.29 (T2DM+oral agents), 2.14 (T2DM+insulin), and 2.35 (T1DM) for all-cause dementia, with similar trends for AD and vascular dementi
Kang S, Ebbels T, Chan Q, Whiley L, Holmes E, Yaffe K, Meyer K, Griffin J 2026 · Metabolomics	observational	supports	low	CARDIA study (n=606, middle-aged): fasting glucose was negatively associated with cognition, with several metabolites mediating the glucose-cognition pathway.
Matsuzaki T, Sasaki K, Tanizaki Y, Hata J, Fujimi K, Matsui Y, Sekita A, Suzuki SO, Kanba S, Kiyohara Y, Iwaki T 2010 · Neurology	observational	supports	high	Autopsy-based Hisayama cohort found higher HOMA-IR/fasting insulin associated with increased neuritic plaque (AD pathology) burden.
Sun J, Xie Z, Wu Y, Liu X, Ma J, Dong Y, Liu C, Ye M, Zhu W 2023 · Am J Prev Med	observational	supports	moderate	Prospective cohort found higher TyG index (insulin-resistance surrogate) associated with increased incident Alzheimer's disease risk.
Cummings JL, Atri A, Sano M, Zetterberg H, Scheltens P, Knop FK, Johannsen P, Wichmann CA, Abschneider RM, Leon T, Feldman HH 2026 · Lancet	RCT	tested-null	high	EVOKE/EVOKE+ phase-3 RCTs: oral semaglutide (GLP-1RA) gave no clinical benefit in early Alzheimer's despite strong observational/preclinical signals — undercuts a simple metabolic-causation-of-established-AD model.
Tseng CH 2026 · Biomed J	observational	mixed	moderate	Epidemiologic review: diabetes raises dementia risk about 56%, but the effect is stronger for vascular dementia than for amyloid-driven Alzheimer's — nuancing the AD-equals-diabetes framing.
Rotonen S, Auvinen J, Bloigu A, Härkönen P, Jokelainen J, Timonen M, Keinänen-Kiukaanniemi S 2026 · Scand J Prim Health Care	observational	supports	moderate	Longitudinal cohort (ages 57-69): greater increases in HOMA-IR (OR 2.20, 95% CI 1.05-4.62) and fasting insulin (OR 3.49, 95% CI 1.48-8.23) increased risk of mild cognitive impairment.
Silva AMP, Gonçalves OR, Tudella GCN, Nascimento MVS, Pereira MAOM, Nantes LAO, Fernandes JVA, Quiroga DG, Lima DVS, Franco ES, Maia MBS 2026 · Rev Neurol	meta-analysis	tested-null	moderate	Meta-analysis of intranasal-insulin RCTs for MCI/AD: evidence inconsistent, no reliable clinical benefit — the direct fix-brain-insulin test does not confirm causation.
Schwartz SS, Rhea EM, Banks WA, Herman ME 2025 · Neuroprotection	observational	supports	low	Mechanistic review: brain hyperinsulinemia, hyperglycemia and insulin resistance are independent AD risk factors via impaired insulin signaling and BBB dysfunction.

Disagree, or know a study we missed?

We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.

📚 Suggest a study ⚑ Flag / request reclassification

Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.